US · ANIP
ANI Pharmaceuticals, Inc.
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Baudette, MN 56623
- Website
- anipharmaceuticals.com
Price · as of 2025-12-31
$80.39
Market cap 1.66B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $96.29 | +19.78% |
| Intrinsic Value(DCF) | $2,258.39 | +2,709.29% |
| Graham-Dodd Method(GD) | $42.52 | -47.11% |
| Graham Formula(GF) | $195.43 | +143.1% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $26.64 | $10.66 | $0.00 | $0.00 | $1,334.84 |
| 2012 | $7.80 | $155.94 | $52.13 | $0.00 | $0.00 |
| 2013 | $34.76 | $364.19 | $261,495.02 | $8.01 | $69.03 |
| 2014 | $60.33 | $1,218.49 | $338,754.56 | $25.75 | $237.50 |
| 2015 | $36.16 | $107.12 | $48.61 | $20.68 | $58.08 |
| 2016 | $48.94 | $105.96 | $1,182.50 | $16.38 | $25.35 |
| 2017 | $62.88 | $87.27 | $1,107.25 | $14.51 | $0.00 |
| 2018 | $63.83 | $188.65 | $1,715.28 | $23.22 | $28.56 |
| 2019 | $42.92 | $93.49 | $60.21 | $20.24 | $5.37 |
| 2020 | $32.34 | $138.40 | $0.00 | $6.63 | $0.00 |
| 2021 | $36.31 | $104.61 | $0.00 | $9.13 | $0.00 |
| 2022 | $40.86 | $918.69 | $0.00 | $2.86 | $0.00 |
| 2023 | $67.42 | $465.43 | $459.72 | $27.71 | $62.17 |
| 2024 | $60.62 | $96.54 | $898.06 | $13.02 | $0.00 |
| 2025 | $75.22 | $96.29 | $8,975.09 | $42.52 | $195.43 |
AI valuation
Our deep-learning model estimates ANI Pharmaceuticals, Inc.'s (ANIP) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $96.29
- Current price
- $80.39
- AI upside
- +19.78%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$2,258.39
+2,709.29% upside
Graham-Dodd
$42.52
-47.11% upside
Graham Formula
$195.43
+143.1% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ANIP | ANI Pharmaceuticals, Inc. | $80.39 | 1.66B | +20% | +2,709% | -47% | +143% | 19.26 | 2.79 | 1.71 | 7.47 | — | -1176.59 | 0.00% | 12.58% | 8.87% | 16.16% | 12.26% | 5.75% | 0.60 | 5.54 | 2.71 | 2.04 | 0.19 | -41923.00% | 4378.00% | 29356.00% | 12.28% | 0.67 | 25.00% | 0.08% | 1.50% | 30.03% | 13.93 | 8.36 | 1.75 | 2.25 |
| BGM | BGM Group Ltd. | $1.11 | 222.69M | +3,719% | +391% | +343% | +545% | -40.44 | 1.44 | 2.44 | 49.11 | — | 1.61 | 16.39% | -2.25% | -5.75% | -3.55% | -1.76% | -2.91% | 0.00 | -0.88 | 3.39 | 2.73 | -11.16 | -8148.00% | -4599.00% | -43.00% | -5.52% | 0.06 | -14.87% | 0.00% | 0.00% | 4.76% | -76.65 | -12.76 | 1.72 | 5.16 |
| HROW | Harrow Health, Inc. | $54.18 | 2.01B | +502% | +346% | — | — | -49.72 | 12.48 | 4.35 | 47.49 | — | -7.40 | 75.33% | 4.42% | -8.76% | -24.97% | 4.11% | -4.99% | 3.29 | 0.39 | 2.08 | 1.79 | 8.21 | -3467.00% | 5332.00% | -5906.00% | -7.00% | -0.24 | -28.36% | 0.00% | 0.00% | 0.00% | 119.11 | -17.26 | 5.26 | 1.98 |
| TLRY | Tilray Brands, Inc. | $7.87 | 796.82M | -67% | -67% | — | — | -0.19 | 0.28 | 0.51 | -0.23 | -0.03 | 0.57 | 29.29% | -277.93% | -266.25% | -88.71% | -84.34% | -68.11% | 0.22 | -55.23 | 2.46 | 1.35 | -0.05 | 65170.00% | 484.00% | 11348.00% | -30.24% | -0.34 | -4.97% | 0.00% | 0.00% | 12.04% | -0.22 | -3.87 | 0.60 | -5.74 |
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
- CEO
- Nikhil Lalwani
- Employees
- 897
- Beta
- 0.52
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($2,258.39 ÷ $80.39) − 1 = +2,709.29% (DCF, example).